Drug comparisons
Repaglinide vs Pramlintide
Repaglinide is an oral meglitinide that stimulates glucose-dependent insulin release for mealtime control in type 2 diabetes, while Pramlintide is an injectable amylin analog that slows gastric emptying and reduces postprandial glucose, often as adjunct to insulin with black box warning for hypoglycemia.
No comparison dimensions are available for this page.
Clinical context
Patients with type 2 diabetes may compare Repaglinide, an oral antidiabetic, and Pramlintide, an injectable amylin analog, when selecting between oral monotherapy and adjunct therapy options.
Bottom line
Repaglinide and Pramlintide are distinct antidiabetic agents with different mechanisms and indications, and the choice depends on individual patient needs and treatment goals.
All medication comparisons